This book is a guide to psychotropic drug therapy for children and adolescents. But just how common is the medical prescription of such drugs at the moment? Is it too little or too much? Does clinical application precede scientific verification of safety and efficacy? Are recommendations for patient management generally followed in everyday clinical settings? This chapter examines these and related issues to the extent that available data will allow.


Mental Retardation Behavior Disorder Psychotropic Medication Psychotropic Drug Tourette Syndrome 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Abramowicz M (ed): Sudden death in children treated with a tricyclic antidepressant. Med Lett Drugs Ther 32:53, 1990.Google Scholar
  2. 2.
    Biederman J: Sudden death in children with a tricyclic antidepressant. J Am Acad Child Adolesc Psychiatry 30:495–498, 1991.PubMedCrossRefGoogle Scholar
  3. 3.
    Riddle MA, Nelson JC, Kleinman CS, et al: Sudden death in children receiving Norpramin: A review of three reported cases and commentary. J Am Acad Child Adolesc Psychiatry 30:104–108, 1991.PubMedCrossRefGoogle Scholar
  4. 4.
    Sprague RL, Gadow KD: The role of the teacher in drug treatment. School Rev 85:109–140, 1976.CrossRefGoogle Scholar
  5. 5.
    Hong SH, Shepherd MD: Psychosocial and demographic predictors of pediatric psychotropic medication use. Am J Health-Syst Pharm 53:1934–1939, 1996.PubMedGoogle Scholar
  6. 6.
    Gadow KD: Prevalence of drug treatment for hyperactivity and other childhood behavior disorders, in Gadow KD, Loney J (eds): Psychosocial Aspects of Drug Treatment for Hyperactivity. Boulder, Colo, Westview Press, 1981, pp 13–76.Google Scholar
  7. 7.
    Maynard R: Omaha pupils given “behavior” drugs. Washington Post, June 29, 1970.Google Scholar
  8. 8.
    Hentoff N: The drugged classroom. Evergreen Review, December, 1970, pp 31–33.Google Scholar
  9. 9.
    Ladd ET: Pills for classroom peace. Saturday Review, November 21, 1970, pp 66–68, 81–83.Google Scholar
  10. 10.
    Rogers JM: Drug abuse—Just what the doctor ordered. Psychology Today, September, 1971, pp 16–24.Google Scholar
  11. 11.
    Gates D: Just saying no to Ritalin. Newsweek, November 23, 1987, p 6.Google Scholar
  12. 12.
    Johnson P: Family: Remedy led to “hell.” USA Today, April 27, 1988.Google Scholar
  13. 13.
    Schmidt WE: Sales of drugs are soaring for treatment of hyperactivity. New York Times, May 5, 1987.Google Scholar
  14. 14.
    Stephen K, Sprague RL, Werry J: Drug treatment of hyperactive children in Chicago (Progress Report of NIMH Grant No. MH 18909, 1970–1973, RL Sprague, Principal Investigator). Urbana, 111, Children’s Research Center, 1973.Google Scholar
  15. 15.
    Sprague RL, Sleator E: Effects of psychopharmacological agents on learning disorders. Pediatr Clin North Am 20:719–735, 1973.PubMedGoogle Scholar
  16. 16.
    Safer DJ, Krager JM: A survey of medication treatment for hyperactive/inattentive students. JAMA 260:2256–2258, 1988.PubMedCrossRefGoogle Scholar
  17. 17.
    Safer DJ, Krager JM: Hyperactivity and inattentiveness: School assessment of stimulant treatment. Clin Pediatr 28:216–221, 1989.CrossRefGoogle Scholar
  18. 18.
    Safer DJ, Allen RP: Absence of tolerance to the behavioral effects of methylphenidate in hyperactive and inattentive children. J Pediatr 115:1003–1008, 1989.PubMedCrossRefGoogle Scholar
  19. 19.
    Safer DJ, Zito JM, Fine EM: Increased methylphenidate usage for attention deficit disorder in the 1990s. Pediatrics 98:1–5, 1996.Google Scholar
  20. 20.
    Gadow KD, Kalachnik J: Prevalance and pattern of drug treatment for behavior disorders of TMR students. Am J Ment Defic 85:588–595, 1981.PubMedGoogle Scholar
  21. 21.
    Divoky D: Toward a nation of sedated children. Learning 1:7–13, 1973.Google Scholar
  22. 22.
    Bosco JJ, Robin SS: Ritalin usage: A challenge to teacher education. Peabody J Educ 53:187–193, 1976.CrossRefGoogle Scholar
  23. 23.
    Gadow KD: School involvement in pharmacotherapy for behavior disorders. J Spec Educ 16:385–399,1982.CrossRefGoogle Scholar
  24. 24.
    Gadow KD: Pharmacotherapy for behavior disorders: Typical treatment practices. Clin Pediatr 22:48–53, 1983.CrossRefGoogle Scholar
  25. 25.
    Loney J, Ordona TT: Using cerebral stimulants to treat minimal brain dysfunction. Am J Orthopsychiatry 45:564–572, 1975.PubMedCrossRefGoogle Scholar
  26. 26.
    Sandoval J, Lambert N, Yandell W: Current medical practice and hyperactivity. Am J Orthopsychiatry 46:323–334, 1976.PubMedCrossRefGoogle Scholar
  27. 27.
    Solomons G: Drug therapy: Initiation and follow-up. Ann NY Acad Sci 205:335–344, 1973.PubMedCrossRefGoogle Scholar
  28. 28.
    Weithorn CJ, Ross R: “Who monitors medication?” J Learn Disabil 8:458–461, 1975.CrossRefGoogle Scholar
  29. 29.
    Bennett FC, Sherman R: Management of childhood “hyperactivity” by primary care physicians. J Dev Behav Pediatr 4:88–93, 1983.PubMedCrossRefGoogle Scholar
  30. 30.
    Brulle AR, Barton LE, Foskett JJ: Educator/physician interchanges: A survey and suggestions. Educ Training Ment Retard 18:313–317, 1983.Google Scholar
  31. 31.
    Copeland L, Wolraich M, Lindgren S, et al: Pediatricians’ reported practices in the assessment and treatment of attention deficit disorders. J Dev Behav Pediatr 8:191–197, 1987.PubMedCrossRefGoogle Scholar
  32. 32.
    Jensen PS, Xenakis SN, Shervette RE, et al: Diagnosis and treatment of attention deficit disorder in two general hospital clinics. Hosp Community Psychiatry 40:708–712, 1989.PubMedGoogle Scholar
  33. 33.
    Sindelar PT, Meisel CJ: Teacher-physician interaction in the treatment of children with behavioral disorders. Int J Partial Hosp 1:271–277, 1982.Google Scholar
  34. 34.
    Aman MG, Singh NN (eds): Psychopharmacotherapy of the Developmental Disabilities. Berlin, Springer-Verlag, 1988.Google Scholar
  35. 35.
    Gadow KD, Poling AD: Pharmacotherapy and Mental Retardation. Austin, Tex, PRO-ED, 1988.Google Scholar
  36. 36.
    Gualtieri CT, Sprague RL, Cole JO: Tardive dyskinesia litigation and the dilemmas of neuroleptic treatment. J Psychiatry Law 14:187–216, 1986.Google Scholar
  37. 37.
    Sprague RL: Litigation, legislation, and regulations, in Breuning SE, Poling AD (eds): Drugs and Mental Retardation. Springfield, 111, Charles C Thomas, 1982, pp 377–414.Google Scholar
  38. 38.
    Sprague RL, Galliher L: Litigation about psychotropic medication, in Gadow KD, Poling AD: Pharmacotherapy and Mental Retardation. Austin, Tex, PRO-ED, 1988, pp 297–312.Google Scholar
  39. 39.
    Aman MG, Sarphare G, Burrow WH: Psychotropic drugs in group homes: Prevalence and relation to demographic/psychiatric variables. Am J Ment Retard 99:500–509, 1995.PubMedGoogle Scholar
  40. 40.
    Hill BK, Balow EA, Bruininks RH: A national study of prescribed drugs in institutions and community residential facilities for mentally retarded people. Psychopharmacol Bull 21:279–284, 1985.PubMedGoogle Scholar
  41. 41.
    Hill BK, Lakin KC, Bruininks RH: Trends in residential services for mentally retarded people: 1977–1982. J Assoc Persons Severe Handicaps 9:243–250, 1984.Google Scholar
  42. 42.
    Aman MG, Field CJ, Bridgman GD: City-wide survey of drug patterns among noninstitutionalized retarded persons. Appl Res Ment Retard 6:159–171, 1985.PubMedCrossRefGoogle Scholar
  43. 43.
    Cullinan D, Gadow KD, Epstein MH: Psychotropic drug treatment among learning disabled, mentally retarded, and seriously emotionally disturbed students. J Abnorm Child Psychol 15:469–477, 1987.PubMedCrossRefGoogle Scholar
  44. 44.
    Hauser WA, Hesdorffer DC: Epilepsy: Frequency, Causes, and Consequences. New York, Demos, 1990.Google Scholar
  45. 45.
    Aman MG, Rojahn J, King EH, Logsdon DA, Marshburn EC: Prevalence and pattern of prescribed medication in 2-year old children. J Dev Phys Dis 6:87–99, 1994.CrossRefGoogle Scholar
  46. 46.
    Emerson R, D’Souza BJ, Vining EP, et al: Stopping medication in children with epilepsy. N Engl J Med 304:1125–1129, 1981.PubMedCrossRefGoogle Scholar
  47. 47.
    Holowach J, Thurstone DL, O’Leary J: Prognosis in childhood epilepsy: Followup study of 148 cases, in which therapy had been suspended after prolonged anticonvulsant control. N Engl J Med 286:169–174,1972.PubMedCrossRefGoogle Scholar
  48. 48.
    Todt H: The late prognosis of epilepsy in childhood: Results of a prospective followup study. Epilepsia 25:137–144, 1984.PubMedCrossRefGoogle Scholar
  49. 49.
    Gadow KD: School involvement in the treatment of seizure disorders. Epilepsia 23:215–224, 1982.PubMedCrossRefGoogle Scholar
  50. 50.
    Pietsch S (ed): The Person with Epilepsy: Life Style, Needs, Expectations. Chicago, National Epilepsy League, 1977.Google Scholar
  51. 51.
    Deykin EY, MacMahon B: The incidence of seizures among children with autistic symptoms. Am J Psychiatry 126:1310–1312, 1979.Google Scholar
  52. 52.
    Gillberg C: The treatment of epilepsy in autism. J Autism Dev Disord 21:61–77, 1991.PubMedCrossRefGoogle Scholar
  53. 53.
    Volkmar FR, Nelson DS: Seizure disorders in autism. J Am Acad Child Adolesc Psychiatry 29:127–129,1990.PubMedCrossRefGoogle Scholar
  54. 54.
    Alvarez N: Discontinuance of antiepileptic medications in patients with developmental disability and diagnosis of epilepsy. Am J Ment Retard 93:593–599, 1989.PubMedGoogle Scholar
  55. 55.
    Beghi E, Bollini P, DiMascio R, et al: Effects of rationalizing drug treatment of patients with epilepsy and mental retardation. Dev Med Child Neurol 29:363–369, 1987.PubMedCrossRefGoogle Scholar
  56. 56.
    Collacott RA, Dignon A, Hauck A, et al: Clinical and therapeutic monitoring of epilepsy in a mental handicap unit. Br J Psychiatry 155:522–525, 1989.PubMedCrossRefGoogle Scholar
  57. 57.
    Sivenius J, Savolaninen S, Kaski M, et al: Therapeutic intervention in mentally retarded adult epileptics. Acta Neurol Scand 81:165–167, 1990.PubMedCrossRefGoogle Scholar
  58. 58.
    Rimland B: Controversies in the treatment of autistic children: Vitamin and drug therapy. J Child Neurol 3(suppl):S68-S72, 1988.CrossRefGoogle Scholar
  59. 59.
    Aman MG, Van Bourgodien ME, Wolford PL, Sarphare G: Psychotropic and anticonvulsant drugs in subjects with autism: Prevalence and patterns of use. J Am Acad Child Adolesc Psychiatry 34:1672–1681, 1995.PubMedCrossRefGoogle Scholar
  60. 60.
    Kovacs M, Feinberg TL, Crouse-Novak MA, et al: Depressive disorders in childhood: I. A longitudinal prospective study of characteristics and recovery. Arch Gen Psychiatry 41:229–237, 1984.PubMedCrossRefGoogle Scholar
  61. 61.
    Keller MB, Lavori PW, Beardslee WR, et al: Depression in children and adolescents: New data on ‘under-treatment’ and a literature review on the efficacy of available treatments. J Affect Disord 21:163–171, 1991.PubMedCrossRefGoogle Scholar
  62. 62.
    Keller MB, Klerman GL, Lavori PW, et al: Treatment received by depressed patients. JAMA 248:1848–1855, 1982.PubMedCrossRefGoogle Scholar
  63. 63.
    Miller FJW: Children who wet the bed, in Kolvin I, MacKeith RC, Meadow SR (eds): Clinics in Developmental Medicine: Bladder Control and Enuresis. New York, JB Lippincott, 1973, pp 47–57.Google Scholar
  64. 64.
    Foxman B, Valdez RB, Brook RH: Childhood enuresis: Prevalence, perceived impact, and prescribed treatments. Pediatrics 77:482–487, 1986.PubMedGoogle Scholar
  65. 65.
    Stefl ME, Bornstein RA, Hammond L: The 1987 Ohio Tourette Survey. Milford, Ohio, Tourette Syndrome Association of Ohio, 1988.Google Scholar
  66. 66.
    Ahsanuddin KM, Ivey JA, Schlotzhauer D, et al: Psychotropic medication prescription patterns in 100 hospitalized children and adolescents. J Am Acad Child Adolesc Psychiatry 22:361–364, 1983.CrossRefGoogle Scholar
  67. 67.
    Patton K, Personal communication, March 8, 1989.Google Scholar
  68. 68.
    Kaplan SL, Simms RM, Busner J: Prescribing practices of outpatient child psychiatrists. J Am Acad Child Adolesc Psychiatry 33:35–44, 1994.PubMedCrossRefGoogle Scholar
  69. 69.
    Simeon JG, Wiggin DM, Williams E: World wide use of psychotropic drugs in child and adolescent psychiatric disorders. Prog Neuro-Psychopharmacol Biol Psychiatry 19:455–465, 1995.CrossRefGoogle Scholar
  70. 70.
    Barkley RA, Fischer M, Newby RF, et al: Development of a multimethod clinical protocol for assessing stimulant drug response in children with attention deficit disorder. J Clin Child Psychol 17:14–24, 1988.CrossRefGoogle Scholar
  71. 71.
    Fine S, Jewesson B: Active drug placebo trial of methylphenidate: A clinical service for children with an attention deficit disorder. Can J Psychiatry 34:447–449, 1989.PubMedGoogle Scholar
  72. 72.
    Gadow KD, Nolan EE, Paolicelli LM, et al: A procedure for assessing the effects of methylphenidate on hyperactive children in public school settings. J Clin Child Psychol 20:268–276, 1991.CrossRefGoogle Scholar
  73. 73.
    Pelham WE, Hoza J: Behavioral assessment of psychostimulant effects on ADD children in a summer day treatment program, in Prinz R (ed): Advances in Behavioral Assessment of Children and Families. Greenwich, Conn, JAI Press, 1987, vol 3, pp 3–34.Google Scholar
  74. 74.
    Sleator EK, von Neumann A: Methylphenidate in the treatment of hyperkinetic children. Clin Pediatr 13: 19–24, 1974.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1999

Authors and Affiliations

  • Kenneth D. Gadow
    • 1
  1. 1.Department of Psychiatry & Behavioral ScienceState University of New York at Stony BrookStony BrookUSA

Personalised recommendations